HK Stock Market Move | HAIXI PHARMA (02637) rose more than 8% after performance announcement, with a net profit for the 25th year increasing by over 30% year-on-year. HAITONG was newly selected for the national VBP program specifications.

HAIXI PHARMA (02637) rose more than 8% after the performance report was released, with an increase of 8.06% to HK$172.9 by the time of publication, with a turnover of HK$621.715 million. On the news front, on March 31, HAIXI PHARMA announced its performance for 2025, with revenue of approximately RMB 582 million, a year-on-year increase of 24.79%; net profit of approximately RMB 177 million, a year-on-year increase of 30.09%; and earnings per share of RMB 2.55. The announcement stated that the increase in revenue was mainly attributed to the Group's enhanced marketing efforts during the year, driving sales revenue growth for Haihuitong and Anbilu. In particular, Haihuitong was newly selected for the national VBP program specifications (5mg / 20mg 14 tablets) in 2025, effectively promoting the expansion of hospital channels and the growth of sales in the terminal market.